Akorn, Inc. (NasdaqGS:AKRX) is looking for acquisition opportunities. Duane Portwood, Chief Financial Officer of Akorn, said, We are focused on expanding our alternate dosage form portfolio both organically through R&D, as well as inorganically through strategic and accretive mergers and acquisitions. Looking forward, we will continue to pursue our multi-pronged acquisition strategy. We are continually evaluating opportunities to bolster our core product lines, human generics, animal health, branded OTC and branded Rx. We seek tuck-in acquisitions of alternate dosage form products, legacy brand products that are either soon to be or already genericized, branded ophthalmology products that can be detailed by our field sales force and OTC health and wellness brands that can add to our growing branded OTC portfolio. In terms of companies, we look to acquire companies with alternate dosage form portfolios that are complementary to our existing portfolio and/or companies that have capabilities to manufacture alternate dosage forms that are new to Akorn, and that have a path to continued growth in a promising pipeline.